TOP1288

January 10, 2018January 10, 2018

Phase 1 Results Support Development of TopiVert Therapy for Ulcerative Colitis

News

Positive safety data from a Phase 1 trial supports TopiVert’s continued development of TOP1288 to treat ulcerative colitis, the British pharma company announced. TOP1288 targets several important enzymes including P38, Src, Lck and ... Read more

March 2, 2017

TopiVert Begins Phase 1 Study of Oral TOP1288 as Colitis Treatment

News

The first participant has been dosed in a Phase 1 American study evaluating TopiVert Pharma‘s oral version of TOP1288 as a treatment for ulcerative colitis (UC). The study will assess TOP1288’s ... Read more

October 6, 2016October 19, 2016

First Ulcerative Colitis Patients Dosed in Phase 2a Trial of TopiVert’s New Therapy

News

The first patients have been dosed in TopiVert’s Phase 2a trial to assess the effectiveness, safety, and tolerability of TOP1288 (rectal form) for moderate to severe symptomatic ulcerative colitis. TopiVert focuses on developing narrow spectrum kinase ... Read more